UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies

Therapeutic Advances in Hematology, 2016-02, Vol.7 (1), p.3-16

Ommen, Hans Beier

2016

Volltextzugriff (PDF)

Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse

British journal of haematology, 2021-11, Vol.195 (3), p.310-327

2021

Volltextzugriff (PDF)

Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia

Blood, 2011-11, Vol.118 (22), p.5905-5913

2011

Volltextzugriff (PDF)

Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia

British journal of haematology, 2020-07, Vol.190 (2), p.198-208

2020

Volltextzugriff (PDF)

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort

Haematologica (Roma), 2020-10, Vol.105 (10), p.2432-2439

2020

Volltextzugriff (PDF)

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5195-5201

2009

Volltextzugriff (PDF)

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

Journal of clinical oncology, 2024-04, Vol.42 (10), p.1158-1168

2024

Volltextzugriff (PDF)

Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene

British journal of haematology, 2014-06, Vol.165 (5), p.618-628

2014

Volltextzugriff (PDF)

Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1A Expression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia

The Journal of molecular diagnostics : JMD, 2021-12, Vol.23 (12), p.1787-1799

2021

Volltextzugriff (PDF)

Acute myeloid leukemia exhibiting clonal instability during treatment: Implications for measurable residual disease assessments

Experimental hematology, 2022-03, Vol.107, p.51-59

2022

Volltextzugriff (PDF)

Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia

Seminars in hematology, 2015-07, Vol.52 (3), p.184-192

2015

Volltextzugriff (PDF)

Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child‐specific reference values

Pediatric blood & cancer, 2019-06, Vol.66 (6), p.e27671-n/a

2019

Volltextzugriff (PDF)

hMICL and CD123 in combination with a CD45/CD34/CD117 backbone – a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia

British journal of haematology, 2014-01, Vol.164 (2), p.212-222

2014

Volltextzugriff (PDF)

Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia

British journal of haematology, 2022-08, Vol.198 (4), p.693-702

2022

Volltextzugriff (PDF)

Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning

European journal of haematology, 2024-04, Vol.112 (4), p.601-610

2024

Volltextzugriff (PDF)

Platelet Function and Turnover in Essential Thrombocythemia: A Systematic Review

Seminars in thrombosis and hemostasis, 2021-02, Vol.47 (1), p.90-101

2021

Volltextzugriff (PDF)

Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission - methodologies in relation to their clinical situation

British journal of haematology, 2012-09, Vol.158 (5), p.569-580

2012

Volltextzugriff (PDF)

Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias

Blood, 2010-01, Vol.115 (2), p.198-205

2010

Volltextzugriff (PDF)

The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients

European journal of haematology, 2015-11, Vol.95 (5), p.436-441

2015

Volltextzugriff (PDF)

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

EClinicalMedicine, 2023-04, Vol.58, p.101939-101939, Article 101939

2023

Volltextzugriff (PDF)

Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000–2016: a Danish population‐based study

British journal of haematology, 2021-05, Vol.193 (3), p.482-487

2021

Volltextzugriff (PDF)

Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML

Blood, 2012-08, Vol.120 (7), p.1473-1484

2012

Volltextzugriff (PDF)

1 – 25 von 191

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(173)
Mit Volltextzugriff
(171)

Publikationsform

Sprache

Englisch
(188)
Dänisch
(3)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(124)
Life Sciences & Biomedicine
(109)
Humans
(91)
Biological And Medical Sciences
(49)
Female
(45)
Male
(45)
Hematology
(42)
Medical Sciences
(41)
Genetics & Heredity
(31)
Adult
(23)
Leukemia, Myeloid, Acute - Genetics
(22)
Animals
(21)
Middle Aged
(20)
Mutation
(20)
Aged
(17)
Biochemistry & Molecular Biology
(16)
Hematologic And Hematopoietic Diseases
(14)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(14)
Acute Myeloid Leukemia
(13)
Adolescent
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies

Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse

Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia

Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1A Expression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia

Acute myeloid leukemia exhibiting clonal instability during treatment: Implications for measurable residual disease assessments

Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia

Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child‐specific reference values

hMICL and CD123 in combination with a CD45/CD34/CD117 backbone – a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia

Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia

Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning

Platelet Function and Turnover in Essential Thrombocythemia: A Systematic Review

Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission - methodologies in relation to their clinical situation

Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias

The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphoma

Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000–2016: a Danish population‐based study

Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial

Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML

Aktive Filter

Suchergebnisse filtern